Pharmacokinetics of 18F-labeled trovafloxacin in normal and Escherichia coli-infected rats and rabbits studied with positron emission tomography

Clinical Microbiology and Infection

Volumn 3, Issue 1, 1997, Pages 63-72

  Fischman, Alan J ^a,b   Babich, John W ^a   Alpert, Nathaniel M ^a   Vincent, John ^c   Wilkinson, Robert A ^a   Callahan, Ronald J ^a   Correia, John A ^a   Rubin, Robert H ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c PFIZER INC   (United States)

Author keywords

Non invasive; PET; Pharmacokinetics; Rabbits; Rats; Trovafloxacin

Indexed keywords

FLUORINE 18; TROVAFLOXACIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD; BRAIN; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG LIVER LEVEL; DRUG TISSUE LEVEL; ENTEROBACTER INFECTION; ESCHERICHIA COLI; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; KIDNEY; LIVER; LUNG; MALE; MINIMUM INHIBITORY CONCENTRATION; MYOSITIS; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RABBIT; RAT; SKELETAL MUSCLE; THIGH;

ANIMALIA; ENTEROBACTER; ENTEROBACTERIACEAE; ESCHERICHIA COLI; ORYCTOLAGUS CUNICULUS;

EID: 0030998574     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.1997.tb00253.x     Document Type: Article

References (33)

1. Eliopoulos GM, Klimm K, Eliopoulos CT, Ferraro MJ, Moellering RC. In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of Gram-positive bacteria [Abstract 752]. In: Program and Abstracts of the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy, Anaheirn, California. Washington DC: American Society for Microbiology, 1992: 236.
2. Ehopoulos GM, Klimm K, Eliopoulos CT, Ferraro MJ, Moellering RC. In vitro activity of CP-99,219, a new fluoroquinolone, against clinical isolates of Gram-positive bacteria. Antimicrob Agents Chemother 1993; 37: 366-70.
3. Briggs-Gooding BB, Jones RN. In vitro antimicrobial activity of CP-99,219, a novel azabicyclo-naphthyridone. Antimicrob Agents Chemocher 1993; 37: 349-53.
4. Gooding BB, Jones RN. In vitro antimicrobial activity of CP-99,219, a novel azabicyclonaphthyridone Antimicrob Agents Chemother 1993; 37: 349-53.
5. Gootz TD, Brighty KH, Anderson MR, et al In vitro activity of CP-99,219, a novel 7-(3-azabicyclo[3.1.0]hexyl) naphthyridone antimicrobial. Diagn Microbiol Infect Dis 1994; 19: 235-43.
6. Knapp JS, Neal SW, Parekh MC, Rice RJ. in vitro activity of a new fluoroquinolone, CP-99,219, against strains of Neissseria gonorrhoeae Antimicrob Agents Chemother 1995; 39: 987-9.
7. Neu HC, Chin NX. In vitro activity of the new fluoroquinolone CP-99,219. Antimicrob Agents Chemother 1994; 38: 2615-22.
8. Spangler SK, Jacobs MR, Appelbaum PC. Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillintazobactam against 489 anaerobes. Antimicrob Agents Chemother 1994, 38: 2471-6.
9. Azoulay-Dupus E, Bedos JP, Valee E, Pocidalo JJ Comparative activity of fluorinated quinolones in acute and subacute Streptococcus pneumoniae pneumonia models: efficacy of temafioxacin. J Antimicrob Chemocher 1991; 28(Suppl. C): 45-53.
10. Girard AE, Faiella JA, Cimochowski CR, Brighty KE. In vivo oral activity of CP-99,219 in models of acute and localized infection [Abstract 1510]. In: Program and Abstracts of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans. Washington DC: American Society for Microbiology, 1993: 395.
11. Nau R, Schmidt T, Kaye K, Froula JL, Tauber MG. Quinolone antibiotics in the therapy of experimental pneumococcal meningitis in rabbits. J Antimicrob Chemother (submitted).
12. Mann HJ, Bitterman PB, Anderson AC, et al. Trovafioxacin (CP-99,219) penetration into human bronchial tissues and fluids following the administration of a single dose [Abstract F241]. In: Program and Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. Washington DC: American Society for Microbiology, 1995: 155.
13. Teng R, Tensfeldt TG, Liston TE, Foulds G. Determination of trovafloxacin, a new quinolone antibiotic, in biological samples by reversed phase high performance liquid chromatography. J Chromatogr 1996; 675: 53-9.
14. 18F-labeled nuconazole in healthy human subjects by positron emission tomography. Antimicrob Agents Chemother 1993; 37: 1270-7.
15. 18F-labeled fluconazole in rabbits with Candidal infections studied with positron emission tomography. J Pharmacol Exp Ther 1991; 259: 1351-9
16. 18F-labeled fleroxacin in rabbits with E. coli infections studied with positron emission tomography Antimicrob Agents Chemother 1992; 36: 2286-92 .
17. 18F]fleroxacin in normal human subjects studied with positron emission tomography. Antimicrob Agents Chemother 1993; 37: 2144-52.
18. 18F]fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studied wich positron emission tomography. Antimicrob Agents Chemother 1996; 40: 659-64.
19. 18F-labeled fluconazole and positron emission tomography studies in rabbits. Int J Nucl Med Biol Part B 1992; 19: 191-9.
20. 18F-labeled fleroxacin. Int J Nucl Med Biol Part B 1993; 20: 81-7.
21. Rubin RH, Livni E, Babich J, et al. Tissue pharmacokinetics of fleroxacin in humans as determined by positron emission tomography. Int J Antimicrob Agents 1994; 4: 15-20.
22. Tewson TJ. Synthesis of fluorine-18 lomefloxacin, a fluorinated quinolone antibiotic. J Labeled Compds Radiopharm 1993; 32. 145-6.
23. 18F] Radiolabeling and biodistribution of the novel fluoro-quinolone antimicrobial agent, trovafloxacin (CP 99,219). Nucl Med Biol (in press).
24. Kilbourn MG, Welch MJ. A simple low volume target for N-13 and F-18 production. J Nucl Med 1983; 24: 120.
25. Baker HC, Lindsey RJ, Weisbroth SH. In: The laboratory rat. New York: Academic Press, 1980: 259.
26. Rota Kops E, Herzog H, Schmid A, Holte S, Femendegen LE. Performance characteristics of an eight-ring whole body PET scanner. J Comput Assist Tomogr 1990; 14(3): 437-45.
27. Duncan DB. Multiple range tests and multiple F-tests. Biometrics 1955; 11: 1-42.
28. Dalvie D, Navetta K, Khosla N. Excretion and metabolism of a new quinolone antibiotic, CP-99,219 in Sprague-Dawley rats and beagle dogs. In: Program and Abstracts of the Sixth North American Meeting of the International Society of Study of Xenobiotics, Raleigh, North Carolina. 1994.
29. Dalvie D, Khosla N, Vincent J. Metabolism of a new quinolone antibiotic, CP-99,219, in humans. In: Program and Abstracts of the International Meeting of the International Society of Study of Xenobiotics, Seattle Washington. 1995.
30. Yamaguchi H. Estimation of internal radiation dose for various physiques using MIRD adult absorbed fractions. Acta Radiol Oncol Radiat Phys Biol 1978; 17: 429-39.
31. Wolfson JS, Hooper DC. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev 1989; 2: 378-424.
32. Girard AE, Girard D, Gootz TD, Faiella JA, Cimochowski CR. In vivo efficacy of trovafloxacin (CO-99,219), a new quinolone with extended activities against Gram-positive pathogens. Streptococcus pneumoriae, and Bacteroides fragilis. Antimicrob Agents Chemother 1995; 39: 2210-16.
33. Kocagoz S, Gür D, Unal S, Akalin HE. In vitro activity of CP-99,219 (trovafloxacin) against Gram-positive clinical isolates [Abstract F231]. In: Program and Abstracts of the 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco. Washington DC: American Society for Microbiology, 1995: 153.